Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) has received a consensus recommendation of “Hold” from the six analysts that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $9.40.
A number of brokerages have weighed in on RXRX. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Jefferies Financial Group dropped their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th.
Check Out Our Latest Stock Report on RXRX
Insider Buying and Selling
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals during the third quarter worth about $25,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $26,000. GAMMA Investing LLC increased its position in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares in the last quarter. Amalgamated Bank raised its holdings in Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the third quarter valued at approximately $69,000. 89.06% of the stock is owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Stock Performance
Shares of RXRX stock opened at $6.61 on Wednesday. The stock’s 50-day moving average price is $6.73 and its 200 day moving average price is $7.76. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.57 billion, a PE ratio of -4.13 and a beta of 0.80. Recursion Pharmaceuticals has a 52-week low of $4.97 and a 52-week high of $15.74.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the previous year, the company posted ($0.38) EPS. The firm’s quarterly revenue was up 30.9% compared to the same quarter last year. As a group, equities research analysts forecast that Recursion Pharmaceuticals will post -1.58 EPS for the current year.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- What Makes a Stock a Good Dividend Stock?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is a Dividend King?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.